April 21, 2016 / 9:47 AM / a year ago

BRIEF-Helix Biopharm says trial steering committee made recommendation to initiate phase II component of LDOS002 study

1 Min Read

April 21 (Reuters) - Helix Biopharma:

* Trial Steering Committee Recommends Initiation Of Phase II L DOS47 study in non-small cell lung cancer

* Says trial steering committee recommendation to initiate phase II component of LDOS002 study

Source text for Eikon:

Further company coverage: (Bengaluru Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below